依托考昔与甲芬那酸治疗原发性痛经的疗效比较：一项随机对照试验。

The efficacy of etoricoxib vs mefenamic acid in the treatment of primary dysmenorrhoea: a randomised comparative trial.

作者信息

Nor Azlin M I, Maryasalwati I, Norzilawati M N, Mahdy Z A, Jamil M A, Zainul Rashid M R

机构信息

Department of Obstetrics and Gynaecology, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

出版信息

J Obstet Gynaecol. 2008 May;28(4):424-6. doi: 10.1080/01443610802150051.

DOI:10.1080/01443610802150051

PMID:18604680

Abstract

Dysmenorrhoea is painful menstruation that occurs in 45-72% of all women. This was a prospective randomised study of the efficacy of etoricoxib (Arcoxia) compared with mefenamic acid (Ponstan) in treating primary dysmenorrhoea. All single, sexually inactive women with primary dysmenorrhoea were randomised into two groups (mefenamic acid and etoricoxib) of pain relief and underwent a cross-over study. The success of treatment as evidenced by pain relief, the side-effects and complications were observed and analysed. Some 80% (20 women) had significantly better pain relief with etoricoxib, compared with only 20 per cent in the mefenamic acid group (p = 0.007). Etoricoxib has significantly fewer side-effects compared with mefenamic acid (p = 0.005) with significantly reduced menstrual blood loss (p = 0.025). In conclusion, etoricoxib is a better treatment for primary dysmenorrhoea with better pain relief, less menstrual blood loss and fewer side-effects compared with mefenamic acid.

摘要

痛经是指45%至72%的女性都会出现的疼痛性月经。这是一项前瞻性随机研究，比较了依托考昔（Arcoxia）与甲芬那酸（Ponstan）治疗原发性痛经的疗效。所有患有原发性痛经的单身、无性生活女性被随机分为两组（甲芬那酸组和依托考昔组）进行疼痛缓解治疗，并进行了交叉研究。观察并分析了以疼痛缓解为依据的治疗成功率、副作用和并发症。约80%（20名女性）服用依托考昔后疼痛缓解明显更好，而甲芬那酸组只有20%（p = 0.007）。与甲芬那酸相比，依托考昔的副作用明显更少（p = 0.005），月经失血量也显著减少（p = 0.025）。总之，与甲芬那酸相比，依托考昔是治疗原发性痛经的更好药物，它能更好地缓解疼痛，减少月经失血量，副作用也更少。